Compare PGR & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGR | VRTX |
|---|---|---|
| Founded | 1937 | 1989 |
| Country | United States | United States |
| Employees | 70000 | 6400 |
| Industry | Property-Casualty Insurers | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.2B | 135.6B |
| IPO Year | 2009 | 2006 |
| Metric | PGR | VRTX |
|---|---|---|
| Price | $228.53 | $526.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 32 |
| Target Price | $230.38 | ★ $571.46 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 10-14-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | 33.54 | ★ 836.54 |
| EPS | ★ 10.47 | 8.33 |
| Revenue | ★ $87,671,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | N/A | $10.54 |
| Revenue Next Year | $5.30 | $9.74 |
| P/E Ratio | ★ $21.90 | $64.00 |
| Revenue Growth | 16.32 | ★ 46.20 |
| 52 Week Low | $189.20 | $403.16 |
| 52 Week High | $239.38 | $560.25 |
| Indicator | PGR | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 55.79 |
| Support Level | $201.16 | $493.75 |
| Resistance Level | $239.38 | $531.78 |
| Average True Range (ATR) | 5.07 | 12.57 |
| MACD | 1.52 | 3.53 |
| Stochastic Oscillator | 93.49 | 77.83 |
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 27 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).